title: Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab.
abstract: BACKGROUND
  The emergence of new biological therapies showing high and sustained level of Psoriasis Area and Severity Index (PASI) 90 response has provided the possibility of both greater skin clearance and increased quality of life (QOL).
  
  
  OBJECTIVE
  To evaluate the association of greater response in skin clearance with improvements in skin-related QOL up to 52 weeks.
  
  
  METHODS
  Subjects achieving various levels of skin clearance (PASI 90-100 or PASI 75-89) and Dermatology Life Quality Index (DLQI) (0/1) response were compared using ERASURE and FIXTURE trial data. Similar analyses with IGA ratings of Clear or Almost Clear were performed.
  
  
  RESULTS
  Significantly more PASI 90-100 responders at week 12 had DLQI 0/1 response than PASI 75-89 (69.4% vs. 47.1%; p < .001) and sustained DLQI 0/1 response at week 52 (74.0% vs. 56.7%; p < .001). IGA results were similar.
  
  
  CONCLUSIONS
  These results show that PASI 90-100 is a relevant therapeutic goal in moderate to severe psoriasis compared to PASI 75-89 when considering patients' QOL.
authors.affiliation: a University of Alabama at Birmingham , Birmingham , AL , USA.
authors.forename: Boni E
authors.initials: BE
authors.lastname: Elewski
authors.affiliation: b Department of Dermatology , Hospital de la Sanat Creu i Sant Pau , Barcelona , Spain.
authors.forename: Lluís
authors.identifier: http://orcid.org/0000-0001-6083-0952
authors.initials: L
authors.lastname: Puig
authors.affiliation: c RTI Health Solutions , Ann Arbor , MI , USA.
authors.forename: Margaret
authors.initials: M
authors.lastname: Mordin
authors.affiliation: d Novartis Pharma AG , Basel , Switzerland.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Gilloteau
authors.affiliation: e RTI Health Solutions , Research Triangle Park , NC , USA.
authors.forename: Bintu
authors.initials: B
authors.lastname: Sherif
authors.affiliation: d Novartis Pharma AG , Basel , Switzerland.
authors.forename: Todd
authors.initials: T
authors.lastname: Fox
authors.affiliation: e RTI Health Solutions , Research Triangle Park , NC , USA.
authors.forename: Ari
authors.initials: A
authors.lastname: Gnanasakthy
authors.affiliation: d Novartis Pharma AG , Basel , Switzerland.
authors.forename: Charis
authors.initials: C
authors.lastname: Papavassilis
authors.affiliation: f University of Connecticut Health Center , Farmington , CT , USA.|g Probity Medical Research , Waterloo , Canada.
authors.forename: Bruce E
authors.initials: BE
authors.lastname: Strober
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D054796:Drug Dosage Calculations; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D015990:Placebo Effect; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D011788:Quality of Life; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; C555450:secukinumab
keywords: DLQI; IGA; PASI; Psoriasis; patient-reported outcome; secukinumab